Accustem Sciences Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
5 PENN PLAZA, 19TH FLOOR, NEW YORK, NY, 10001
Mailing Address
5 PENN PLAZA, 19TH FLOOR, NEW YORK, NY, 10001
Phone
442070661000
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$1.55M
Total Assets
-$2.11M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | April 14, 2026 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
| 4 Insider stock transaction report | June 16, 2025 | View on SEC |
| 4 Insider stock transaction report | June 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 20, 2025 | View on SEC |
| 4 Insider stock transaction report | April 10, 2025 | View on SEC |
| 4 Insider stock transaction report | April 8, 2025 | View on SEC |
| 10-K Annual financial report | April 3, 2025 | View on SEC |
Annual Reports
10-K
April 14, 2026
- Developing two innovative genomic tests: MSC for lung nodules and StemPrintER for breast cancer.
- Operates a lean, clinical-stage model with only four full-time employees.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.